axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.
Company profile
Ticker
AXSM
Exchange
Website
CEO
Herriot Tabuteau
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Axsome Therapeutics Australia Pty Ltd • Axsome Therapeutics, Limited • Axsome International Holdings LLC • Axsome Malta Holdings Ltd. • Axsome Malta Ltd. • Axsome Canada, Inc. ...
AXSM stock data
Latest filings (excl ownership)
8-K
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
25 Mar 24
8-K
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
25 Mar 24
8-K
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
19 Mar 24
10-K
2023 FY
Annual report
23 Feb 24
8-K
Corporate Presentation February 2024
20 Feb 24
8-K
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
20 Feb 24
8-K
Corporate Presentation January 2024
8 Jan 24
8-K
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
4 Jan 24
8-K
Other Events
7 Dec 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
Transcripts
AXSM
Earnings call transcript
2023 Q4
20 Feb 24
AXSM
Earnings call transcript
2023 Q3
6 Nov 23
AXSM
Earnings call transcript
2023 Q2
7 Aug 23
AXSM
Earnings call transcript
2023 Q1
8 May 23
AXSM
Earnings call transcript
2022 Q4
27 Feb 23
AXSM
Earnings call transcript
2022 Q3
7 Nov 22
AXSM
Earnings call transcript
2022 Q2
9 Aug 22
AXSM
Earnings call transcript
2022 Q1
2 May 22
AXSM
Earnings call transcript
2021 Q4
1 Mar 22
AXSM
Earnings call transcript
2021 Q3
8 Nov 21
Latest ownership filings
4
ROGER JEFFS
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
4
ROGER JEFFS
29 Feb 24
4
Mark E Saad
29 Feb 24
4
Mark L. Jacobson
29 Feb 24
4
Nick Pizzie
29 Feb 24
4
HERRIOT TABUTEAU
29 Feb 24
4
Susan Mahony
29 Feb 24
4
Hunter R. Murdock
29 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 416.56 mm | 416.56 mm | 416.56 mm | 416.56 mm | 416.56 mm | 416.56 mm |
Cash burn (monthly) | 6.85 mm | (no burn) | 20.96 mm | 16.60 mm | 17.85 mm | 11.86 mm |
Cash used (since last report) | 40.92 mm | n/a | 125.20 mm | 99.17 mm | 106.62 mm | 70.83 mm |
Cash remaining | 375.65 mm | n/a | 291.37 mm | 317.39 mm | 309.94 mm | 345.74 mm |
Runway (months of cash) | 54.8 | n/a | 13.9 | 19.1 | 17.4 | 29.2 |
Institutional ownership, Q3 2023
79.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 223 |
Opened positions | 25 |
Closed positions | 33 |
Increased positions | 85 |
Reduced positions | 70 |
13F shares | Current |
---|---|
Total value | 2.62 tn |
Total shares | 37.63 mm |
Total puts | 363.00 k |
Total calls | 568.10 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
RTW Investments | 4.49 mm | $313.78 bn |
Vanguard | 3.73 mm | $260.63 bn |
BLK Blackrock | 2.93 mm | $205.09 bn |
Fairmount Funds Management | 2.34 mm | $163.63 bn |
BVF | 2.13 mm | $148.94 bn |
FMR | 1.86 mm | $129.89 bn |
Citadel Advisors | 1.30 mm | $90.55 bn |
Deep Track Capital | 1.14 mm | $79.73 bn |
Ra Capital Management | 1.00 mm | $69.89 bn |
STT State Street | 867.65 k | $60.64 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Jeffs Roger | Common Stock | Sell | Dispose S | No | No | 71.6072 | 2,347 | 168.06 k | 120,756 |
15 Mar 24 | Jeffs Roger | Common Stock | Option exercise | Acquire M | No | No | 29.91 | 2,347 | 70.20 k | 123,103 |
15 Mar 24 | Jeffs Roger | Stock Option Common Stock | Option exercise | Dispose M | No | No | 29.91 | 2,347 | 70.20 k | 0 |
14 Mar 24 | Jeffs Roger | Common Stock | Sell | Dispose S | No | No | 69.702 | 16,976 | 1.18 mm | 120,756 |
14 Mar 24 | Jeffs Roger | Common Stock | Option exercise | Acquire M | No | No | 25.53 | 16,976 | 433.40 k | 137,732 |
14 Mar 24 | Jeffs Roger | Common Stock | Sell | Dispose S | No | No | 69.702 | 13,000 | 906.13 k | 120,756 |
14 Mar 24 | Jeffs Roger | Common Stock | Option exercise | Acquire M | No | No | 22.03 | 13,000 | 286.39 k | 133,756 |
14 Mar 24 | Jeffs Roger | Stock Option Common Stock | Option exercise | Dispose M | No | No | 25.53 | 16,976 | 433.40 k | 0 |
14 Mar 24 | Jeffs Roger | Stock Option Common Stock | Option exercise | Dispose M | No | No | 22.03 | 13,000 | 286.39 k | 0 |
27 Feb 24 | Hunter R. Murdock | RSU Common Stock | Grant | Acquire A | No | No | 0 | 12,956 | 0.00 | 12,956 |
News
Mizuho Maintains Buy on Axsome Therapeutics, Raises Price Target to $109
28 Mar 24
Truist Securities Maintains Buy on Axsome Therapeutics, Maintains $150 Price Target
26 Mar 24
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
26 Mar 24
RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $128
26 Mar 24
Citigroup Maintains Buy on Axsome Therapeutics, Raises Price Target to $127
26 Mar 24
Press releases
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
25 Mar 24
Thinking about trading options or stock in Arm Holdings, UiPath, Dell Technologies, Digital World Acquisition, or Axsome Therapeutics?
25 Mar 24
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
25 Mar 24
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
25 Mar 24
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
27 Feb 24